Associate Professor Beale is Director of Cancer Services and Director of Palliative Care, Sydney Local Health District, Head of Medical Oncology Department at Concord Hospital, Senior Staff Specialist at RPA, and at Chris O’Brien Lifehouse and Associate Professor at the University of Sydney.  He has a special interest in ovarian, breast, colorectal and upper gastrointestinal cancers and is involved in Phase I, II and III clinical trials for all of these cancers and is the PI in several breast and ovarian cancer trials. He has published more than 100 peer reviewed papers.  He is the Chair of ANZGOG and is a member of the AGITG and ANZBCTG trials groups.

Alison Brand is a gynaecological oncology surgeon, Director of Gynaecological Oncology at Westmead Hospital, Sydney, NSW and Clinical Associate Professor at the University of Sydney. She has been involved in ANZGOG since it was established in 2000 and has since held key positions within the group. She is a member of the Cancer Australia Gynaecological Cancer Advisory Group and has chaired or been a member of several working parties for the development of national gynaecological cancer guidelines. She is Senior Editor for the International Journal of Gynaecological Cancer. She is passionate about participation in clinical trials as a way to improve the lives of women with gynaecological cancers, now and in the future.

Sue Brew has been a member of the ANZGOG Study Coordinators’ committee since its inception in 2005 and accepted the position as committee chair in 2011. She has been a Study Coordinator in the Department of Medical Oncology, Calvary Mater Newcastle since 1996 and also recently served as member of Hunter New England Human Research Ethics Committee for a period of 8 years 2006 – 2014.

Alison Davis is a Senior Staff Specialist in Medical Oncology at The Canberra Hospital and Conjoint Senior lecturer at the Australian National University. Her subspeciality areas include gynaecological and breast cancer and she is actively involved in clinical research in both areas. Her other interest areas include Cancer Genetics and End of life care. Alison has been involved with ANZGOG for many years and was Deputy Chair of the ANZGOG RAC for two years before becoming Chair in late 2017. She has also been a member of the ANZGOG Audit, ASM and New Research Fund Committees, as well as a member of other regional and national organisations including Advisory Committee Pharmaceutical Medicines 2008-2015, ACT SE NSW Breast Cancer Treatment Group, Australian Breast Cancer Tissue Bank and is Chair of the Capital Region Cancer Services Morbidity and mortality committee.

Dr Pearly Khaw is a Radiation Oncologist at the Peter MacCallum Cancer Centre. She is also a clinical researcher and is leading the Radiation Oncology Quality Assurance Program of the PORTEC-3 trial in Australia through the Trans-Tasman Radiation Oncology Group (TROG). Dr Khaw has been a reviewer for the International Journal of Gynecological Cancer, Journal of Medical Imaging and Radiation Oncology, and Practical Radiation Oncology. She was involved in the formation of the Special Interest Group for Radiation Oncologists practising in the area of Gynae-Oncology through the Royal Australian and New Zealand College of Radiologists. Pearly is the Primary Investigator on the ANZGOG endometrial trial STATEC.

Linda Mileshkin is a clinical researcher who has achieved productive research output whilst maintaining a significant and busy clinical role as a consultant medical oncologist, with a particular interest in the treatment of gynaecological and lung cancers, as well as the supportive care of people affected by cancer. She runs the only specialist Carcinoma of Unknown Primary clinic at the Peter MacCallum Cancer Centre. She is currently involved in multiple clinical research projects involving people gynaecological and lung cancers, carcinoma of unknown primary (CUP), as well as Phase I trials in multiple tumour types.  Linda is currently the international study chair for Outback, an international Australia-led NHMRC funded Phase III trial in cervical cancer.

Clare Scott is a Medical Oncologist at the Royal Melbourne Hospital and Royal Women’s Hospital and Laboratory Head at the Walter and Eliza Hall Institute of Medical Research, studying drug resistance in ovarian cancer. She has 15 years’ experience in clinical cancer genetics, including working in Familial Cancer Clinics and in treating breast and ovarian cancer. In the lab, she focuses on ovarian biology, including the role of apoptosis in infertility and on developing targeted therapies for ovarian cancer in novel ovarian cancer models. She has been awarded a Clinical Fellowship from the Victorian Cancer Agency (2011) and the Sir Edward Dunlop Cancer Research Fellow from the Cancer Council Victoria (2012).

Peter Sykes is a gynaecological oncologist and Head of Department, Obstetrics and Gynaecology, Christchurch School of Medicine, University of Otago, Christchurch, New Zealand. He completed his initial training in Bristol, UK and has worked on both Australia and New Zealand. His interest area of clinical research in the epidemiology and management of gynaecological cancer has involved a steady record of publication in clinical gynaecological oncology.  He has actively recruited and treated patients in international multicentre and single centre research.  He is on the ANZGOG Research Advisory Committee and was Program Chair of the 2014 ANZGOG ASGO Combined Scientific Meeting and is Program Chair of the 2015 ANZGOG Annual Scientific Meeting.

David Rogers was with professional services firm KPMG for 37 years, including 27 years as a partner in the Australian firm. His career has included audit partner and lead partner for many significant companies in a wide range of sectors. In addition, David was a member of the firm’s National  Board of directors for 6 years from 2005 to 2011 including 2 years as Chairman of the firm’s Audit Committee and was prior to his retirement leader of the firm’s global audit transformation project.

David is currently a director and honorary treasurer of the Royal Motor Yacht Club Broken Bay.

Rachael is a Partner in the Holman Webb Workplace Relations group and has 19 years’ experience in employment and workplace law. Rachael is experienced in all aspects of workplace laws and has a strong background in advising public and private sector employers. Rachael was admitted to practice law in October 1997 and has been a partner at Holman Webb since January 2012. She also specialises in food safety and labelling laws and has acted as a prosecutor for the NSW Food Authority for some 14 years. She now advises food businesses including start-ups in this area. Rachael has presented to many Boards of Directors and senior management teams on employment and work health and safety laws, what due diligence means and how best to comply. Rachael is a member of the NSW Law Society and Industrial Relations Society of NSW.

Paul Cohen is a clinician researcher at the Western Australian Gynaecological Cancer Service, King Edward Memorial Hospital, and St John of God Subiaco Hospital, Western Australia. He is a Clinical Associate Professor at the University of Western Australia and Adjunct Professor at the Institute for Health Research, University of Notre Dame Australia.

His research interests include patient-reported outcomes and the supportive care of women affected by gynaecological malignancies, gynaecological cancer genetics, the management of patients with cervical pre-cancer and cancer, the epidemiology of gynaecological malignancies and biomarkers to predict histological tumour regression in women with high-grade serous ovarian cancer following neoadjuvant chemotherapy. He is a co-investigator in a number of clinical trials.

Paul is the current program chair of the ANZGOG Annual Scientific Meeting. He is a member of the Australian eviQ National Guidelines Cancer Genetics Reference Committee, ANZGOG Cervix Tumour Type Working Group, Australian Clinical Trial Alliance Impact and Implementation Committee, IGCS Education Committee and is a member of the Editorial Board of the International Journal of Gynecological Cancer.